Development of 1-(substituted benzofuran-2-yl)-3-(halogen-substituted phenyl)prop-2-en-1-ones as potent, reversible, and selective MAO-B inhibitors for Parkinson’s Disease Authors: Ali Hasan, Jiseong Lee, Naresh Payyaula, Vishnu Vasanthi Radhakrishanan, Sachithra Thazhathuveedu Sudevan, Sunil Kumar, Della Grace Thomas Parambi, Kasim Sakran Abass, Arun Kumar, Naseer Maliyakkal, Hoon Kim, Bijo Mathew Published: 2026 ABSTRACT AbstractTen halogenated benzofuran derivatives (BF1–BF10) were synthesized and evaluated for their inhibitory activity against monoamine oxidase isoforms. All compounds showed stronger inhibition of MAO-B compared to MAO-A. Among them, BF2 exhibited the most potent MAO-B inhibition (IC₅₀ = 0.082 µM), followed by BF5 (IC₅₀ = 0.095 µM) and BF1 (IC₅₀ = 0.16 µM), with high selectivity indices, particularly BF2 (SI = 1038.05). Kinetic studies revealed that BF2 acts as a competitive inhibitor with a Ki value of 0.083 ± 0.0056 µM. Dialysis experiments confirmed its reversible inhibition profile, comparable to the reference drug Safinamide. Both BF2and BF5 were non-cytotoxic toward L929 cells and demonstrated moderate blood–brain barrier permeability in PAMPA assay. Molecular docking showed stabilization of MAO-B via π–π stacking interactions with Tyr326 and Tyr398, and molecular dynamics simulations further confirmed stable binding of BF2 within the MAO-B active site. Overall, BF2 emerged as a potent, selective, and reversible MAO-B inhibitor, warranting for further investigation.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-53367-w.Keywords: Benzofuran, Chalcone, MAO-B, Reversibility, Kinetics, Molecular dockingSubject terms: Biochemistry, Chemistry, Drug discovery Introduction Parkinson’s disease (PD) is an age-related neurodegenerative disorder and is the second most common progressive neurodegenerative condition associated with motor disabilities. This condition affects approximately 2% of adults over 65 years of age1,2, with 5–20 cases reported annually, contributing to a global population of around 100,000 individuals. In patients with PD, dopamine (DA) are reduced in the caudate nucleus and putamen. The disease is characterized by the specific loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by the presence of cytosolic Lewy bodies that contain aggregated α-synuclein3–5.In addition to motor symptoms, PD patients often experience non-motor symptoms such as depression, sleep disturbance, and cognitive impairment6.Although the exact cause of the condition’s progression is unknown, several studies suggest that beyond DA depletion, various factors may also act as contributors. These include protein aggregation, oxidative stress, neuroinflammation, dysregulation of the autophagy-lysosomal pathway, insufficient neurotrophic factor support, and mitochondrial dysfunction7.Since the late 1950s, monoamine oxidase (MAO) inhibitors have been employed, and since the end of the 1960s, supplements consisting of short biogenic molecules containing 3,4-dihydroxyphenylalanine (L-DOPA) have been used8. MAOare the main enzymes that use oxidative deamination to metabolize various biogenic amines9. Several neurological conditions, including PD disease and Alzheimer’s disease (AD), are directly correlated with changes in biogenic amine concentrations in the brain10. The toxic consequences of oxidative breakdown include the production of hydrogen peroxide, reactive oxygen species (ROS), and ammonia. In brain cells, these byproducts can cause oxidative stress and mitochondrial dysfunction11,12. Patients with PD have high levels of MAO-B in the substantia nigra, and reversible and highly selective MAO-B inhibitors have shown promise in treating PD symptoms13. Reversible MAO-B inhibitors such as rasagiline and selegiline are beneficial for treating motor dysfunction and DA degradation in patients with PD. Irreversible MAO-B inhibitors have several disadvantages, including immunogenicity of the MAO-B inhibitor adduct, prolonged half-life, disruption of the target, decreased sensitivity to ADME testing, and de novo MAO enzyme synthesis in the human brain14–16.These elements have led to a surge in interest in the development of reversible and efficient MAO-B inhibitors for PD treatment. The FDA and EU recently approved the reversible MAO-B inhibitor safinamide for the treatment of individuals with mid- to late-stage PD17,18. The FDA approved drugs and benzofuran containing MAO inhibitors are depicited in Fig. 1. MAO inhibitors (safinamide, selegiline, and rasagiline) and some approved benzofuran compounds (bergapten and amiodarone). Chalcones, also known as trans-1,3-diphenyl-2-propen-1-ones, are simple chemical scaffolds that contain enone linkers between two phenyl or heteroaryl nuclei19. The chalcone scaffold underwent numerous structural modifications to function as a selective MAO-B inhibitor. These modifications include the insertion of different electron-donating and/or electron-withdrawing groups into the two aromatic heterocyclic rings to produce potent, selective and reversible type of MAO-B inhibitors20. These investigations have shown that the important parameters in the development of MAO-B inhibitors include the length and hydrophobicity of the rings and electron delocalization enone linker in the chalcone moiety21–23. These reports suggest that the presence of halogen-containing compounds can produce the electron-acceptor nature of MAO-B inhibitors through halogen bonding, which is favorable for interactions24,25. SwissTargetPredictions, an online tool, was recently used for ligand-based target prediction by looking for comparable molecules. Our lab discovered that the basic chalcone skeleton is more selective towards oxidase enzymes like MAO-B20. Benzofuran is a bicyclic heteroaromatic nucleus with a variety of pharmacological properties including anticancer, antimicrobial, anti-inflammatory, antiviral, antioxidant, and neuroprotective effects. Moreover, the nucleus has a significant role in the development of MAO inhibitors in recent years. Considering the role of the chalcone scaffold, the presence of halogens, and the benzofuran nucleus in the development of MAO-B inhibitors, we aimed to incorporate all these structural units into a single framework. This is consistent with our ongoing endeavors to develop potent and specific MAO-B inhibitors for the treatment of PD26–28. This study focuses on the synthesis and MAO inhibition of halogenated benzofuran-based chalcones. The lead molecules were further evaluated for their reversibility, kinetics, blood-brain barrier (BBB) permeation, and cytotoxicity. Materials and methods Chemicals For the synthesis, 2-benzofuranyl methyl ketone and halogenated benzaldehydes(Sigma Aldrich, St. Louis, MO, USA) were used. For the enzyme inhibition study, enzymes (recombinant human MAO-A and MAO-B) and chemicals, including benzylamine, kynuramine, safinamide mesylate salt, pargyline, clorgyline, and toloxatone, were purchased from Sigma Aldrich. The DiaEasy™ dialysis kit (6–8 kDa) was obtained from BioVision (St. Louis, MA, USA), as described previously. Synthesis A mixture of 2-benzofuranyl methyl ketone (0.01 M) and one of the aldehyde derivatives (0.01 M) in methanol (20 mL) was cooled to 0–5 °C after which 15 mL of 40% aqueous sodium hydroxide was added. The mixture was stirred at 25 °C for 6 h (Scheme 1). The mixture was then poured onto crushed ice and acidified with Conc. HCl. The precipitated solids were filtered, washed with water, and dried, andthe residue was recrystallized with ethanol. The reaction was monitored by TLC using hexane and ethyl acetate (4:1). Structures of all final derivatives were investigated by using 1H NMR and13C NMR spectra obtained with an NMR spectrometer (Bruker Advance Neo 500 MHz, Billerica, MA, USA). Synthetic scheme of chalcone base benzofuran derivatives (BF1-BF10). Enzyme assays and kinetics The activities of recombinant human MAO-A and MAO-B were assayed using kynuramine (0.06 mM) and benzylamine (0.30 mM), respectively, by continuously measuring the absorbance changes at 316 and 250 nm, respectively29,30. Enzyme activity was assayed at five substrate concentrations around the Km value in the absence of an inhibitor of enzyme kinetics. Inhibition studies of MAO-A and MAO-B by the compounds For the inhibition study, residual activity was initial screened by measuring the absorbance change in the presence of a 10 µM inhibitor.If necessary, a 1 µMconcentration was used for potent inhibitors. IC50 values were then determined for compounds with less than 80% residual activity at 10 µM using residual activity curves generated by GraphPad Prism software 8.030. The upper limit of IC50 was set to 100 µM. IC50 values of the leading compounds BF2 and BF5 were analyzed by dose-response curves constructed at seven inhibitor concentrations. The selectivity index (SI) for MAO-B was calculated using the IC50 values for MAO-A and the IC50 of MAO-A/MAO-B31. The inhibition type of a lead compound BF2 for MAO-B was determined at three inhibitor concentrations around (approximately 1/2 x, 1 x, and 2 x IC50) and five different substrate concentrations (0.0375–0.6 µM)32. Enzyme kinetic patterns and Ki values were determined by comparing Lineweaver-Burk plots and their secondary plots33. Toloxatone, clorgyline, safinamidemesylate salt, and pargyline were used as the reference compounds. Time-dependency and reversibility studies Time-dependent inhibition of BF2 for MAO-B was observed by preincubation at designated times, i.e., 0, 2, 5, 10, 15, and 30 min. Concentration of BF2 was approximately IC50 (0.1 µM ). After preincubation, the residual activity was measured. The reversibility of BF2 for MAO-B was evaluated by comparing the undialyzed (AU) and dialyzed (AD) residual activities at a concentration of approximately 2-times the IC50 after a 30 min pre-incubation before measurement. Two types of reference inhibitors were used for MAO-A and MAO-B: reversible inhibitors toloxatone and safinamide mesylate (for MAO-A and MAO-B, respectively) and irreversible inhibitors clorgyline and pargyline (for MAO-A and MAO-B, respectively)34. Parallel artificial membrane permeability assay (PAMPA) The PAMPA method35,36 was used to assess the two lead compounds’ blood-brain barrier (BBB) penetration capacities. Supplementary data provide a full explanation of this process. Cytotoxicity test of BF2 and BF5 to L929 cell line The National Center for Cell Science (NCCS), Pune, India, provided the mouse fibroblast cell line L929. The supporting information provides a full explanation of the protocol37,38. Computational studies Absorption, distribution, metabolism, excretion, and toxicity (ADMET) study The ADME/Tox (absorption, distribution, metabolism, excretion, and toxicity) profiles of the synthesized compounds were assessed using the QikProp module from Schrödinger, Inc., New York, USA (2024)(https://www.schrodinger.com/platform/products/qikprop/). This tool estimates key descriptors by benchmarking the compounds against the top five structurally similar drug molecules39,40. The ligands were analyzed and their properties evaluated according to the predicted descriptor values. Molecular Docking The binding affinities of lead molecules BF2 and BF5 towards hMAO-A (PDB ID: 2Z5X) and hMAO-B (PDB ID: 2V5Z) enzymes were determined using molecular docking studies41,42. Protein crystal structures were prepared by adding missing residues and hydrogen atoms, followed by optimization and minimization using the Protein Preparation Workflow program. Protonation states for each residue in the protein at a pH of 7.4.All water molecules in the crystal structure were removed, and the ligand was prepared using the LigPrep module to assign the 3D coordinates and hydrogen atoms at the same pH using the OPLS4 force field. The receptor-grid generation tool was used to assign docking coordinates where the co-crystal ligand was bound. Docking was performed using the default OPLS4 force field with an extra precision (XP) docking pipeline in the Schrodinger software to evaluate the binding affinity of ligands towards both receptors(https://www.schrodinger.com/platform/products/glide/). To understand the binding free energy of the docked complex, molecular mechanics with generalized born surface area calculations were performed using the Prime module in Schrodinger software15. Molecular dynamics simulation Molecular dynamics (MD) simulation was performed for the docked complex of BF2 ligand in the active site of MAO-B receptor using Desmond module in Schrödinger, Inc., New York, USA 2024 -3 software (https://www.schrodinger.com/platform/products/desmond/). The complex was solvated using SPC water molecules in an orthorhombic periodic condition and neutralized the charge using NaCl salt. The electrostatic interaction for simulation was accounted within 9Å cut-off and NPT ensemble with 300 K temperature and 1 bar pressure was chosen for simulation. The temperature and pressure was controlled using Nose-Hoover chain thermostat and Martyna-Tobias-Klein barostat with isotropic coupling style. Finally, the production run was performed for 200ns and the protein-ligand complex stability was analyzed using RMSD, RMSF, and interaction profile of the trajectory43,44. Results Synthesis Total 10 compounds were synthesized according to the Scheme 1 and characterized by using 1H NMR and 13C NMR spectra (Supplementary Information). Inhibition studies of MAO-A and MAO-B Among the 10 compounds, 7 showed low residual activity of < 50% for MAO-B at a concentration of 1 µM, while all compounds exhibited higher residual activity of > 50% for MAO-A at a concentration of 10 µM (Table 1). BF2 had an IC50 value of 0.082 µM, demonstrating the greatest inhibitory ability against MAO-B, followed by compounds BF5 (IC50 = 0.095 µM) and BF1 (IC50 = 0.16 µM). The IC50 values of BF2 and BF5 were analyzed by dose-response curves constructed as shown in Fig. 2. With high SI values for MAO-B (Fig. 3), all compounds exhibitedstronger inhibition of MAO-B than MAO-A. The highest SI values for MAO-B were obtained for BF2 (2-Cl) at 1038.05, BF5 (2-Br) at > 1052.63, and BF1 (-H) at > 625.00. BF2 showed a stronger inhibition than pargyline, a reference irreversible MAO-B inhibitor, but lower inhibitory effect than safinamide, a reference reversible inhibitor. Table 1Inhibitions of MAO-A and MAO-B by benzofuran derivatives.CompoundResidual activity (%)IC50 (µM)SIMAO-A (10µM)MAO-B (1µM)MAO-AMAO-BBF174.14 ± 1.6016.30 ± 2.48> 1000.16 ± 0.041> 625.00BF268.54 ± 6.579.65 ± 0.9885.12 ± 1.270.082 ± 0.0211038.05BF393.49 ± 2.01344.68 ± 6.23> 1000.94 ± 0.16> 106.38BF487.04 ± 1.8764.34 ± 7.81> 1001.67 ± 0.20> 59.88BF576.60 ± 4.816.89 ± 2.04> 1000.095 ± 0.016> 1052.63BF681.27 ± 2.6758.52 ± 0.43> 1001.90 ± 0.023> 52.63BF783.39 ± 5.6654.69 ± 6.63> 1001.27 ± 0.23> 78.74BF877.66 ± 7.7738.59 ± 0.18> 1000.79 ± 0.0077> 126.58BF982.87 ± 7.8525.58 ± 1.3990.57 ± 1.740.21 ± 0.0019431.29BF1081.25 ± 0.2818.17 ± 2.12> 1000.19 ± 0.0059> 526.32Toloxatone––1.65 ± 0.094> 400.041Safinamide––> 400.019 ± 0.00192105.26Clorgyline––0.008 ± 0.0012.43 ± 0.710.0033Pargyline––2.15 ± 0.230.11 ± 0.0119.55 Inhibitions of MAO-A and MAO-B by benzofuran derivatives. IC50 analysis of BF2 and BF5 against MAO-B using dose-response curves. Structure-activity relationship of chalcone-based benzofuran derivatives. All BF series compounds are benzofuran derivatives with a parent structure in which a carbonyl functional group is bonded to position 2 of benzofuran (Fig. 3), followed by methyl styrene. The subtypes were named according to the substituents bonded to the benzene ring on the right: -Cl was bonded from BF2 to BF4, -Br from BF5 to BF7, and -F from BF8 to BF10 (Fig. 3). Overall, Cl substituents showed better inhibitory activity than Br and F-substituents in order (Table 1). In addition, for the Cl substituents, the inhibitory effect was found to be the strongest, in the order of ortho, meta, andpara. In the Br-substituents, similar to the Cl-substituents, the best inhibitory effect was observed in the ortho position, but the para position of the substituents showed a better inhibitory effect than the meta position. Finally, for the F substituents, a strong inhibitory effect was observed in the order of para, meta, and ortho.These observed trends suggest that both the nature of the halogen substituent and its positional orientation may influence MAO-B inhibitory activity. The relatively higher activity of chloro-substituted derivatives compared to bromo and fluoro analogues may be associated with a balance between electronic and steric effects; however, this interpretation remains qualitative. Similarly, the preference for ortho substitution in Cl and Br derivatives may indicate a favorable orientation within the MAO-B binding site, although no direct structural evidence is provided in the present study. In contrast, the distinct trend observed for fluoro derivatives may reflect differences in electronic distribution due to the smaller size and higher electronegativity of fluorine. To contextualize the potency of the synthesized compounds, a comparison with previously reported chalcone-based MAO-B inhibitors was performed. The conjugated dione derivatives (CD series) showed moderate to low MAO-B inhibitory activity, and the strength of this activity was greatly affected by the kind of phenyl substitution. Of these, CD8 (4-fluorophenyl) had the strongest effect (IC₅₀ = 0.230 ± 0.01 µM), followed by CD4 (IC₅₀ = 0.307 ± 0.05 µM). CD7 (4-methoxy, IC₅₀ = 2.99 ± 0.48 µM), CD6 (4-bromo, IC₅₀ = 3.46 ± 0.31 µM), and CD5 (4-nitrophenyl, IC₅₀ = 6.01 ± 0.64 µM) (Tabe S1) all had weaker effects43. This pattern shows that tiny electron-withdrawing groups make MAO-B inhibitory action more likely in this series. To provide context for these results, a direct comparison was conducted with a literature-reported chalcone-based MAO-B inhibitor that is closely related. Compound 3i (dihydrobenzofuran–thiophene conjugated chalcone) showed high activity (IC₅₀ = 0.092 µM)45. The benzofuran–chalcone hybrids created in this investigation had similar strength, with BF2 (IC₅₀ = 0.082 ± 0.021 µM) and BF5 (IC₅₀ = 0.095 ± 0.016 µM) both matching or slightly surpassing the activity of 3i. This shows a concentrated comparison that shows how much better BF derivatives are than the CD series. These findings indicate that the inclusion of the benzofuran moiety into the chalcone framework creates an efficient scaffold for MAO-B inhibition and broadens the structural diversity of chalcone-based inhibitors. Results are presented with the means ± standard errors of triplicate experiments. SI, selectivity index (IC50 for MAO-A/IC50 for MAO-B). Enzyme kinetics Enzyme kinetics and inhibition studies were performed using five substrate concentrations and three inhibitor concentrations of BF2. The five concentrations were selected in the range between ~ 1/4x and 4x Km to minimize the data errors in a linear LB plot transformed from a nonlinear regression Michaelis-Menten equation, considering very sensitive to data error in a particular range of substrate concentration in the LB plot. In the Lineweaver-Bulk plot, BF2 exhibited competitive MAO-B inhibition (Fig. 4A), showing unchanged Vmax values at three inhibitor concentrations to the control. From the secondary plots, the Ki value was determined to be 0.083 ± 0.0056 μm (Fig. 4B). Lineweaver–Burk plots for MAO-B inhibitions by BF2(A), and the secondary plots (B) of the slopes vs. inhibitor concentrations.Kmand Vmaxwere 0.23 ± 0.035 mM and 0.0027 dA/min, respectively. Substrate concentrations used were ~ 1/4x, 1/2x, 1x, 2x, and 4x Km. Results are presented with the values obtained from triplicate experiments with error bars. Time-dependency and reversibility studies BF2 showed an instantaneous binding pattern in a time-dependency inhibition test by measuring the residual activityafter preincubationfor up to 30 min (Fig. 5A). The reversibility of MAO-B inhibition by BF2 was analyzed by dialysis after 30 min of pre-incubation. The concentrations of BF2, safinamide, and pargyline used were 2 times their IC50 values (0. 17, 0.038, and 0.22 µM, respectively). Recovery patterns were compared using undialyzed (AU) and dialyzed (AD) relative activities. The inhibition of MAO-B by compound BF2 was recovered from 34.42% to 69.40%. The recovery value of the compound was similar to that of safinamide (reversible type, 22.18–72.54%) and could be distinguished from that of pargyline (irreversible type, 15.70–17.76%) (Fig. 5B). From these results, no slow-binding behavior was observed in time-dependency test and inhibition was recovered to the level of the reversible inhibitor in dialysis assay. Based on these results, it is suggested that BF2 is a reversible MAO-B inhibitor. Time-dependency (A) and reversibility test (B) of MAO-B inhibition by BF2. (A) The residual activities were measured after pre-incubation of BF2(0.1 µM) and MAO-B forthe designated times. (B) The residual activities weremeasuredafter a 30 min pre-incubation at a concentration of approximately 2-times the IC50and dialysisfor 6 h with two buffer changes. Results are the means with error bars of triplicate experiments. Parallel artificial membrane permeability assay (PAMPA) for blood-brain barrier (BBB) permeation study Compounds (BF2 and BF5) showed a significant degree of permeation and CNS bioavailability as determined bythe PAMPA. Specifically, BF2 (Pe = 2.43 ± 0.12 × 10–6 cm/s) is now described as exhibiting moderate/uncertain BBB permeability (CNS±), whereas BF5 (Pe = 9.01 ± 0.09 × 10–6 cm/s) is correctly classified as highly permeable (CNS+) (Table 2). Brain penetration is crucial for the effective delivery of CNS drugs. In this experiment, the PAMPA-BBB assay was used to evaluate the brain permeability of various derivatives. Penetration depth was determined by calculating the effective permeability (Log Pe) of each compound using a specific formula. Compounds with Pe values below 2.0 × 10–6 cm/s are categorized as likely non-penetrating (CNS-), while those with Pe values exceeding 4.0 × 10–6 cm/s are considered potentially permeable (CNS+). Table 2Blood-brain barrierassay of key compounds by PAMPA method.CompoundExperimentalPe (×10− 6 cm/s)PredictionBF22.43 ± 0.12CNS±BF59.01 ± 0.09CNS+Selegiline5.69 ± 0.04CNS+Pe (10− 6cm/s) > 4.00: CNS+ (high permeation); Pe (10− 6 cm/s) < 2.00: CNS− (low permeation); Pe (10− 6 cm/s) from 2.00 to 4.00: CNS± (permeation uncertain). Blood-brain barrierassay of key compounds by PAMPA method. Pe (10− 6cm/s) > 4.00: CNS+ (high permeation); Pe (10− 6 cm/s) < 2.00: CNS− (low permeation); Pe (10− 6 cm/s) from 2.00 to 4.00: CNS± (permeation uncertain). Effect of BF2 and BF5 on cell viability in L929 The L929 cell line, derived from the subcutaneous connective tissue of mice (Mus musculus) and was found to be fibroblast-like. Due to their sensitivity, L929 cells are frequently used to assess the cytotoxicity of various substances, including chemicals, medications, and biomaterials. Cell viability was 75% for BF2 up to 25 µg/mL and 82% for BF5 at 50 µg/mL (Fig. 6). The results led to the determination of IC50 values for BF2 and BF5, which were 55.84 µg/mL (197.51 µM) and > 100 µg/mL (> 305.65 µM), respectively. Morphological alterations in the cells at each dose were observed, and a figure is included in the Supporting Information (Figures S1 and S2). Overall, these results suggest that BF2 and BF5 molecules are non-cytotoxic to the cell line L929 in the ranges higher than 50 and 12.5 µg/mL, respectively. Cell viability of BF2 and BF5 on the L929 cell line analyzed by MTT assay. Statistical significance was evaluated by comparing each treatment group with the control group using an unpaired t-test. Data are presented as mean ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. Computational studies ADMET properties The synthesized compounds were analysed for their in silico drug-likeness properties using ADME/Tox descriptors of QikProp module (Schrödinger, Inc., New York, USA, www.schrodinger.com) provided nearly 50 key parameters, including general criteria such as the Lipinski Rule of Five, as well as specific indicators like logP, BBB permeability, human oral absorption, HERG binding, and logS, as summarized in Table 3. These descriptors are valuable for predicting the the biological activity of the molecules at the molecular level. Table 3ADMET prediction of the BFseries molecules.MoleculeMWRBdonorHBaccptHBQPlogPo/wQPlogSQPlogHERGQPPCacoQPlogBBQPPMDCKQPlogKhsaHOAPSAROF BF1 248.281402.53.777− 3.977− 6.1012921.439− 0.1961576.1770.257336.9530 BF2 282.726402.54.282− 4.745− 6.0432921.776− 0.0333886.1460.385336.9490 BF3 327.177402.54.363− 4.866− 6.0752921.141− 0.0224176.6770.411336.9560 BF4 282.726402.54.217− 4.593− 6.0062923.688− 0.0493455.950.366336.920 BF5 282.726402.54.284− 4.747− 6.0422921.837− 0.0333887.8230.385336.9470 BF6 327.177402.54.292− 4.7− 6.0332923.549− 0.0373719.0690.39336.920 BF7 327.177402.54.36− 4.863− 6.0742922.21− 0.0224178.8230.41336.9440 BF8 266.271402.54.016− 4.351− 5.9872921.684− 0.0862845.6990.303336.950 BF9 266.271402.54.018− 4.354− 5.9882920.92− 0.0862844.0210.304336.9590 BF10 266.271402.53.982− 4.28− 6.0122922.741− 0.1052553.5360.297336.9320MW - Molecular Weight: Typically, between 180 and 500 Da for drug-like compounds. RB - Rotatable Bonds: Less than 10–15 is ideal for good oral bioavailability. donorHB - Hydrogen Bond Donors: Typically, ≤ 5 is desirable for drug-like molecules. accptHB - Hydrogen Bond Acceptors: Typically, ≤ 10 is desirable for drug-like molecules. QPlogPo/w - Logarithm of the Partition Coefficient (LogP): Ideal range for drug-like compounds is between 0 and 5. QPlogS - Logarithm of Solubility (LogS): Solubility greater than − 4.0 is generally acceptable. QPlogHERG - Logarithm of the HERG (Human Ether-à-go-go-Related Gene) binding affinity: Values less than − 5 indicate lower risk for cardiac toxicity. QPPCaco - Predicted Caco-2 Cell Permeability: Values greater than 1 × 10–6 cm/s indicate good permeability. QPlogBB - Logarithm of Blood-Brain Barrier permeability: Values greater than − 1 suggest potential for BBB penetration. QPPMDCK - Predicted MDCK Cell Permeability: Values greater than 1 × 10–6 cm/s are considered to have good permeability. QPlogKhsa - Logarithm of Human Serum Albumin Binding (LogKhsa): A value between − 3 and − 1 is desirable for proper protein binding. HOA – HumanOralAbsorption: Predicted Qualitative Human Oral Absorption: A value of 3 or higher suggests good absorption. PSA - Polar Surface Area: A value less than 140 Ų is generally optimal for drug absorption. ROF – RuleOfFive: Lipinski’s Rule of Five: Molecular weight < 500 Da, LogP < 5, Hydrogen bond donors < 5, Hydrogen bond acceptors < 1. ADMET prediction of the BFseries molecules. MW - Molecular Weight: Typically, between 180 and 500 Da for drug-like compounds. RB - Rotatable Bonds: Less than 10–15 is ideal for good oral bioavailability. donorHB - Hydrogen Bond Donors: Typically, ≤ 5 is desirable for drug-like molecules. accptHB - Hydrogen Bond Acceptors: Typically, ≤ 10 is desirable for drug-like molecules. QPlogPo/w - Logarithm of the Partition Coefficient (LogP): Ideal range for drug-like compounds is between 0 and 5. QPlogS - Logarithm of Solubility (LogS): Solubility greater than − 4.0 is generally acceptable. QPlogHERG - Logarithm of the HERG (Human Ether-à-go-go-Related Gene) binding affinity: Values less than − 5 indicate lower risk for cardiac toxicity. QPPCaco - Predicted Caco-2 Cell Permeability: Values greater than 1 × 10–6 cm/s indicate good permeability. QPlogBB - Logarithm of Blood-Brain Barrier permeability: Values greater than − 1 suggest potential for BBB penetration. QPPMDCK - Predicted MDCK Cell Permeability: Values greater than 1 × 10–6 cm/s are considered to have good permeability. QPlogKhsa - Logarithm of Human Serum Albumin Binding (LogKhsa): A value between − 3 and − 1 is desirable for proper protein binding. HOA – HumanOralAbsorption: Predicted Qualitative Human Oral Absorption: A value of 3 or higher suggests good absorption. PSA - Polar Surface Area: A value less than 140 Ų is generally optimal for drug absorption. ROF – RuleOfFive: Lipinski’s Rule of Five: Molecular weight < 500 Da, LogP < 5, Hydrogen bond donors < 5, Hydrogen bond acceptors < 1. The analysis confirmed that all molecules fully comply with the Lipinski’s Rule of Five. Oral bioavailability, a critical factor for drug efficacy, was supported by all molecules having less than five rotatable bonds (RB) and a polar surface area (PSA) below 200 Ų, and ensuring oral bioavailability safely. Additionally, the human oral absorption (HOA) descriptor indicated a high predicted oral absorption score of 3 for all compounds. The Caco-2 permeability values suggested efficient intestinal absorption, while QPlogKhsa values ranging from − 1.5 to 1.5 reflected favorable human serum albumin binding capacity. TheQlogP values highlighted moderate solubility, and QPlogBB suggested all compounds possess the ability to permeate the BBB. The polar surface area and logP further supported that the compounds exhibit consistent solubility and are capable of crossing the BBB. The predicted ADMET descriptors suggest that all the examined compounds exhibit generally acceptable drug-like properties within the standard range for small-molecule therapeutic candidates. The lead compounds BF2 and BF5 had better permeability while moderate solubility necessitate further tuning during lead optimization. Also, the anticipated QPlogHERG values suggest a possible risk of hERG channel blockage, necessitating further experimentimal assessment. Molecular Docking Enzymatic inhibitory studies showed that compounds BF2 and BF5 were more potent against hMAO-B than hMAO-A. Molecular docking was performed to understand the interaction and affinity of the most potent ligands, BF2 and BF5 for the binding sites of both the hMAO-B and hMAO-A enzymes. The Protein Data Bank was used to obtain the crystal structures of hMAO-B (PDB ID: 2V5Z) and hMAO-A (PDB ID: 2Z5X). The docking was validatedby redocking co-crystalized Safinamide in hMAO-B andHarmine in hMAO-A shows an acceptable RMSD of 1.95and 0.34Å, respectively. The docking scores and binding energy analysis clearly showed that both compounds showed better binding affinities toward MAO-B than toward MAO-A (Table 4). Among the compounds, the BF2 compound has docking score and binding free energy (ΔG) of -10.458 and − 46.17 kcal/mol, respectively, while the compound BF5 has − 10.429 and − 44.54 kcal/mol, respectively, towards hMAO-B. The co-crystal ligand Harmine in hMAO-B receptor interacts with Phe352 with a distance of 4.74 Å while co-crystal ligand in hMAO-A receptor Safinamide interacts with Tyr326 and Gln206 with a distance of 3.89 Å and 2.31 Å respectively Supporting Information (Figures S3). The interaction profile of compounds in the binding site of hMAO-B revealed that the benzofuran moiety of BF2 and BF5 has π-π stacking interaction with Tyr326 while chlorobenzene and bromobenzene of BF2 and BF5 with π-π interaction with Tyr398. Compound BF2 interacts with Tyr326 and Tyr398 in a distance of 4.97 Å and 4.39 Å respectively while the compound BF5 has a bonding distance of 5.02 Å and 4.40 Å respectively Fig. 7A. The van der Waals interactions and electrostatic interactions in the 4.0 Å binding site residues Tyr60, Pro102, Pro104, Trp119, Leu164, Leu167, Phe168, Leu171, Cys172, Tyr188, Ile198, Ile199, Gln206, Ile316, Leu328, Phe343, and Tyr435 of hMAO-B were also favored for the inhibitory action of BF2 and BF5 compounds. Compounds BF2 and BF5 only had a small difference in the docking score owing to the same conformation obtained by the compounds, but the 2 kcal/mol difference in the binding free energy with lower bonding distance might be the reason for showing more potency for BF2 than BF5 in the hMAO-B receptor (Fig. 8). This small difference might be contributing for similar difference in activity between BF2 and BF5 which is evident from IC50 values were BF2 (IC₅₀ = 0.087 ± 0.023 µM) and BF5 (IC₅₀ = 0.097 ± 0.0091 µM) shows marginal difference. Table 4XP Docking Score and Binding Free (ΔG Bind) Energy of Promising Compounds in the active site of hMAO-B and hMAO-A enzymes.CompoundMAO-B (2V5Z)MAO-A (2Z5X)Docking scoreBinding free energy (ΔG)Docking scoreBinding free energy (ΔG) BF2 − 10.458− 46.17− 8.365− 37.14 BF5 − 10.429− 44.54− 5.452− 27.14Values are presented as kcal/mol. XP Docking Score and Binding Free (ΔG Bind) Energy of Promising Compounds in the active site of hMAO-B and hMAO-A enzymes. Values are presented as kcal/mol. Binding interactions of BF2 (yellow) and BF5 (faded salmon) compounds in the active site of the hMAO-B enzyme (PDB ID: 2V5Z) and hMAO-A enzyme (PDB ID:2Z5X). Overlay of docked poses of BF2 (yellow) and BF5 (magenta) in the active site of hMAO-B (A) and distance of interactions (B). The green dash lines indicate Pi-Pi stacking interactions. A thorough investigation in the active site of hMAO-A has revealed that compound BF2 had docking score and binding free energy (ΔG) of -8.365 and − 37.14 kcal/mol, respectively, while the compound BF5 had − 5.452 and − 27.14 kcal/mol, respectively. Both the compounds showed π- π interaction with Phe208 and Tyr407 but the benzene and furan part of the coumaran ring in the BF2 compound were making π-π interaction with Phe208 (4.56 and 3.58 Å) while in the BF5 compound, only benzene part of coumarin ring were having π-π interaction with Phe208 (4.57 Å). A π-π interaction was made by chlorobenzene and bromobenzene with Tyr407 (4.22 and 4.04 Å) by both BF2 and BF5 compounds Fig. 7B. In comparison, compounds BF2 and BF5 did not exhibit greater affinity for the hMAO-A receptor than for the hMAO-B receptor. The chlorobenzene and bromobenzene pharmacophores demonstrated solvent accessibility at the hMAO-B receptor, whereas solvent accessibility was restricted to the active site of the hMAO-A enzyme, favoring a higher affinity towards the hMAO-B enzyme. Molecular dynamics simulation To assess the stability of the BF2 ligand in the MAO-B receptor’s active region, the complex underwent MD modeling. We used the complex’s root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) to assess the average atom displacement in order to analyze the stability of the docked complex. One of the most important factors for determining the stability and structural conformations of complexes during simulation is RMSD. According to RMSD analysis, the ligand and protein C-alpha were monitored within a reasonable range for a lengthy simulation period (200 ns). The ligand (red) RMSD was constant with few deviations, in contrast to the protein RMSD. The average protein RMSD was 2.70Å, with a range of 1.06 to 3.87Å (Fig. 9). With the exception of a little fluctuation, the protein-specific RMSD during the simulation remained consistent, peaking at 3.87Å at 130 ns before stabilizing. An additional metric used to assess the protein’s side chain flexibility is the RMSF. The stability of the complex can be decreased by the ligand binding that is influenced by the side chains’ flexibility at the active site. Although structural domains such as coiled coils and protein structure randomness are extremely flexible regions that might result in larger RMSF values, the fluctuation is reduced with a lower RMSF value. By calculating the RMSF for every protein amino acid residue, the simulation assessed the protein system’s flexibility.MAO-B residues 480–498 exhibited a greater volatility. During the binding process, the atoms in the RMSF ligand’s benzoyl ring (Fig. 9B) displayed minor oscillations. The 22 amino acid residues that had an RMSF value of less than 1Å reacted with the ligand. The interaction histograms of BF2 and MAO-B revealed halogen bonding and hydrophobic interactions (Fig. 9C). The quantity of individual interactions between the ligand and amino acids was normalized over a 200 ns trajectory. Tyr326 (hydrophobic), Tyr398 (hydrophobic), Leu171 (hydrophobic), Cys172 (halogen bond), and Ile199 (hydrophobic) are among the important amino acids that interact with BF2. Nearly 0.6 was the measured proportion of interactions with Tyr326. Tyr326’s hydrophobic interaction with the MAO-B active site was important, as was previously noted36. The lead chemical BF2 is predicted to inhibit MAO-B overall based on the trajectory analysis and comprehensive MD simulation. Desmond’s MD simulation analysis of the BF2-MAO-B complex. (A) Root mean square deviation (RMSD). (B) Individual RMSF for proteins’ amino acids. (C) Protein-ligand contacts with number of specific contacts of amino acids with BF2. Conclusion This study focused on the synthesis and MAO inhibition of ten halogenated benzofuran (BF) derivatives. The level of MAO-B inhibition was higher for all BF compounds. With competitive and reversible modes of action, BF2 and BF5 are selectiveMAO-B inhibitors. Both candidates exhibited moderate to good CNS drug-likeness according to the PAMPA assay. The MTT test on the L929 cell line established that BF2 and BF5 are not cytotoxic, with IC50 values of 55.84 µg/mL and > 100 µg/mL, respectively. Molecular docking and dynamic simulation suggestedthat lead molecule (BF2) have excellent binding interactions in the inhibitor-binding cavity of MAO-B, with favorableinsilico ADME predictions. Although more research is needed to determine their therapeutic value, these compounds show selective MAO-B inhibition in vitro and could be preliminary lead candidates deserving of more study. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University forfunding this work through the Large Research Project under grant number RGP2/330/47. Author contributions B. M. and H. K. contributed the conceptualization, data analysis, editing and review; A. H., N. P. and S. K. participated the synthesis and characterization of the molecules; J. L., D. G. T. P., K. S. A., A. K. and N. M. performed all the biological screening and their data anlysis; V. V. R. and S. T. S. accompled all computational studies. Funding Open access funding provided by Amrita Vishwa Vidyapeetham. The authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University forfunding this work through the Large Research Project under grant number RGP2/330/47. Data availability Data are provided within the manuscript or supplementary information files. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Jiseong Lee and Naresh Payyaula. Contributor Information Hoon Kim, Email: hoon@sunchon.ac.kr. Bijo Mathew, Email: bijomathew@aims.amrita.edu, Email: bijovilaventgu@gmail.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Data are provided within the manuscript or supplementary information files.